Resumen
Definición
Anamnesis y examen
Principales factores de diagnóstico
- presencia de factores de riesgo
- despigmentación de la piel de la zona acral y perioral
- despigmentación de la piel de la zona perianal y genital
- traumatismo cutáneo reciente
- dolor localizado por quemadura solar
- realce y fluorescencia con exposición a radiación UVA
- nevo con halo
- despigmentación universal
Factores de riesgo
- edad <30 años
- antecedentes familiares de vitiligo
- enfermedad autoinmune
- contacto químico
Pruebas diagnósticas
Primeras pruebas diagnósticas para solicitar
- diagnóstico clínico
Pruebas diagnósticas que deben considerarse
- Examen con lámpara de Wood
- biopsia de piel
Algoritmo de tratamiento
vitiligo segmentario o vitiligo limitado
vitiligo generalizado (más del 3% del área de superficie corporal)
Colaboradores
Autores
John E. Harris, MD, PhD
Professor
Department of Dermatology
University of Massachusetts Medical School
Worcester
MA
Divulgaciones
JEH has acted as a consultant and/or investigator for: Pfizer, Genzyme/Sanofi, Aclaris Therapeutics Inc., Incyte, Rheos Medicines, Sun Pharmaceuticals, LEO Pharma, Villaris Therapeutics Inc., Dermavant, Temprian, AbbVie Inc., Janssen, TeVido, BioDevices, EMD Serono, Almirall, Boston Pharma, Sonoma Biotherapeutics Inc., Methuselah Health, Twi Biotech, Pandion, Cogen Therapeutics Inc., Admirx, BridgeBio, AnaptysBio, Avita, Frazier Management. He has equity in TeVido Biodevices, Rheos, and Villaris Therapeutics Inc., and is the Scientific Founder of Villaris Therapeutics Inc. JEH is an author of a number of references cited in this topic.
Mehdi Rashighi, MD
Assistant Professor
Department of Dermatology
University of Massachusetts Medical School
Worcester
MA
Divulgaciones
MR has received consulting fees and/or research grants from the following: Pfizer, AbbVie, Dermavant, LEO Pharma, and Almirall. MR is an author of a reference cited in this topic.
Agradecimientos
Professor John E. Harris and Dr Mehdi Rashighi would like to gratefully acknowledge Dr Bernhard Ortel, a previous contributor to this topic. BO declares that he has no competing interests.
Revisores por pares
Iltefat Hamzavi, MD
Senior Staff Physician
Multicultural Dermatology Center
Henry Ford Hospital
Detroit
MI
Divulgaciones
IH is an author of a number of references cited in this topic.
Piergiacomo Calzavara-Pinton, MD
Chair
Dermatology Department
University of Brescia
Brescia
Italy
Divulgaciones
PC-P is an author of a number of references cited in this topic.
Diferenciales
- Piebaldismo
- Síndrome de Waardenburg
- Esclerosis tuberosa
Más DiferencialesGuías de práctica clínica
- British Association of Dermatologists guidelines for the management of people with vitiligo 2021
- Guidelines for the management of vitiligo
Más Guías de práctica clínica- Inicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad